Lupin signs distribution agreement with Celnova for orphan drug NaMuscla
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for treatment of dry eye syndrome
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
The demand for high-quality paediatric medicines has been growing rapidly in China as a result of the government’s support and policy measures
This is the company’s first partnership arrangement in China
Subscribe To Our Newsletter & Stay Updated